मुख्यपृष्ठ › मल्टिपल मायलोमा › मॅसाच्युसेट्स › Boston
Boston, MA मधील मल्टिपल मायलोमा साठी क्लिनिकल ट्रायल्स
Boston आणि आजूबाजूच्या ठिकाणी (सुमारे 30 मैलांच्या आत) मल्टिपल मायलोमा साठी 42 अभ्यास सहभागी शोधत आहेत. कोण सहभागी होऊ शकते आणि अभ्यास संघाशी संपर्क कसा साधावा हे पाहण्यासाठी अभ्यास उघडा.
अधिकृत अभ्यास मजकूर (इंग्रजी)
अभ्यासासाठी सहभागी शोधत आहात? हे पृष्ठ शीर्षस्थानी दर्शवा — 30 दिवसांसाठी $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
निवड सुरू आहेफेज 3
- Research Site, Boston
- Research Site, Boston
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 3
- Tufts Medical Center, Boston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 3
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
निवड सुरू आहेफेज 3
- Dana Farber / Harvard Cancer Center, Boston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
निवड सुरू आहेफेज 4
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1/2
- Mass General Brigham, Boston
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
निवड सुरू आहेफेज 2
- Beth Israel Deaconess Medical Center, Boston
ELISA in Relapsed/Refractory MM
निवड सुरू आहेफेज 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
निवड सुरू आहेफेज 3
- Boston Medical Center, Boston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
निवड सुरू आहेफेज 1/2
- Dana-Farber Cancer Institute /ID# 271846, Boston
Elranatamab in R/R Multiple Myeloma
निवड सुरू आहेफेज 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Dana Farber Cancer institution, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Massachusetts General Hospital, Boston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
निवड सुरू आहेफेज 3
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
निवड सुरू आहेफेज 1/2
- GSK Investigational Site, Boston
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
निवड सुरू आहेफेज 1/2
- Research Site, Boston
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
निवड सुरू आहेफेज 3
- Tufts Medical Center, Boston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
निवड सुरू आहेफेज 1/2
- Boston Medical Center, Boston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
निवड सुरू आहेफेज 1
- Dana-Farber Cancer Institute, Boston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
निवड सुरू आहेफेज 1/2
- Research Site, Boston
- Research Site, Boston
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
निवड सुरू आहेफेज 2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Selinexor and Backbone Treatments of Multiple Myeloma Patients
निवड सुरू आहेफेज 1/2
- Dana Farber Cancer Institute, Boston
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
निवड सुरू आहेफेज 1
- Dana Farber/Harvard Cancer Center, Boston
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
निवड सुरू आहे
- Dana-Farber Cancer Institute, Boston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
निवड सुरू आहेफेज 3
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Dana Farber Cancer Institute, Boston
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
निवड सुरू आहेफेज 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
निवड सुरू आहेफेज 1
- Dana Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
निवड सुरू आहे
- Massachusetts General Hospital Cancer Center, Boston
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
निवड सुरू आहेफेज 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
निवड सुरू आहेफेज 1/2
- Massachusetts General Hospital, Boston
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1
- Dana-Farber Cancer Institute, Boston
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
निवड सुरू आहे
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
निवड सुरू आहेफेज 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
निवड सुरू आहेफेज 1/2
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
निवड सुरू आहेनिरीक्षण अभ्यास
- Boston University Cancer Research Center, Boston
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
निवड सुरू आहेफेज 1/2
- Dana-Farber Cancer Institute, Boston
इतर शहरांतील मल्टिपल मायलोमा ट्रायल्स
- New York City, NY60 अभ्यास
- Atlanta, GA41 अभ्यास
- Houston, TX38 अभ्यास
- Durham, NC37 अभ्यास
- Nashville, TN32 अभ्यास
- Denver, CO27 अभ्यास
- Rochester, MN24 अभ्यास
- St. Louis, MO24 अभ्यास
- Columbus, OH24 अभ्यास
- Baldwin Park, CA23 अभ्यास
- Chicago, IL22 अभ्यास
- Seattle, WA22 अभ्यास
Boston मधील इतर अभ्यास
- स्तनाचा कर्करोग111 अभ्यास
- नॉन-स्मॉल सेल लंग कॅन्सर90 अभ्यास
- कर्करोग (सर्व प्रकार)86 अभ्यास
- कोलोरॅक्टल कॅन्सर63 अभ्यास
- मेटास्टॅटिक कर्करोग63 अभ्यास
- फुफ्फुसाचा कॅन्सर62 अभ्यास
- अंडाशयाचा कर्करोग61 अभ्यास
- प्रोस्टेट कर्करोग59 अभ्यास
- नैराश्य52 अभ्यास
- एंडोमेट्रियल कर्करोग50 अभ्यास
- हृदयाची अशक्तपणा44 अभ्यास
- अ‍ॅक्युट मायलोइड ल्युकेमिया44 अभ्यास
ClinicalTrials.gov वरून, 5 ऑक्टो, 2026 रोजी मिळालेली माहिती. प्रत्येक अभ्यासासाठी पात्रतेचे निकष वेगळे असतात; अभ्यास संघ ठरवतो की कोण सहभागी होऊ शकते.